Anupam Rasayan
Anupam Rasayan is a publicly listed Indian custom manufacturer of specialty chemicals, producing complex molecules via proprietary continuous flow chemistry for 80+ global pharma, agrochemical, and performance-materials customers across eight manufacturing facilities in India and the US.
- Company typePublic
- Founded1984
- HeadquartersSurat, India
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Anupam Rasayan does
Anupam Rasayan India Limited is a publicly listed (NSE: ANURAS) custom manufacturer of specialty chemicals headquartered in Surat, Gujarat, India, with 1,700+ employees including 90+ scientists and 40+ years of industry experience. The company operates eight manufacturing facilities — six in India and two in the United States (acquired via Jayhawk Fine Chemicals in February 2026) — with a combined installed capacity of approximately 30,000+ MPTA, producing 60+ complex molecules across 30+ commercial chemistries for 80+ global customers in agrochemicals (51% of pre-acquisition revenue), pharmaceuticals, and performance materials/electronics.
The company's core technology is a proprietary continuous flow chemistry platform, which in June 2026 enabled it to become the world's first commercial producer of Ethyl trifluoroacetate (ETFA) — a fluorinated building block serving pharma, life sciences, and performance materials end-markets with a $500-600 million global addressable market. Its products include custom-synthesized agrochemical intermediates and active ingredients, pharmaceutical intermediates and (via Bliss GVS Pharma, announced May 2026) finished dosage formulations including suppositories, injectables, and tablets manufactured at US FDA, WHO-GMP, and EU-GMP approved facilities, and advanced custom synthesis for electronics, aerospace, energy, and polymers via the Jayhawk acquisition.
Anupam Rasayan generates revenue through a B2B custom synthesis and contract development/manufacturing (CDMO) model with quote-based pricing under long-term contracts. FY26 revenue reached Rs 23,836 million (approximately $285M USD), up 65% YoY, with FY26 net profit of Rs 170.12 crore (+82.24% YoY). The company sells directly to enterprise customers in regulated markets via wholly-owned subsidiaries in the US (Delaware, Kansas), Europe (Basel), Japan (Tokyo), and the UAE (Dubai). Recent strategic positioning includes an EcoVadis Silver Medal (Top 15% globally, score 77), UN Global Compact signatory status, and a 2027 net-zero energy target with 39.5% renewable energy share already achieved.
Anupam Rasayan firmographics
Firmographics- Name
- Anupam Rasayan
- Legal name
- Anupam Rasayan India Limited
- Website
- https://anupamrasayan.com
- Company type
- Public
- Founded year
- 1984
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Anupam Rasayan is a publicly listed Indian custom manufacturer of specialty chemicals, producing complex molecules via proprietary continuous flow chemistry for 80+ global pharma, agrochemical, and performance-materials customers across eight manufacturing facilities in India and the US.
- Ownership category
- akta.pro rank
Anupam Rasayan industry classification
Industry- Product category
- Specialty Chemicals Manufacturing
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Industrial Organic Chemicals (2860), Chemicals & Allied Products (2800), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Custom Synthesis & Technical Active Ingredient (AI) Manufacturing (intermediates, actives) (AFABAIAI)
- akta.pro secondary industries
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB)
Keywords
Where Anupam Rasayan is headquartered
LocationHeadquarters
- HQ city
- Surat
- HQ country
- India
- HQ region
- Asia
Offices6 records
Markets served
Anupam Rasayan business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Specialty Chemicals Manufacturing: Custom manufacturing of specialty chemicals for agrochemicals (51% of revenue pre-acquisition), pharmaceuticals, and performance materials segments. Revenue generated through long-term contracts and custom synthesis projects with 80+ global customers.
- Custom Synthesis Services: Contract development and manufacturing (CDMO) services providing custom synthesis of complex molecules for pharmaceutical and specialty chemical applications. Contributed to significant revenue growth with 65% YoY increase in FY26.
- Pharmaceutical Formulations: Entry into finished dosage formulations through acquisition of Bliss GVS Pharma, expanding from key starting materials into finished dosage formulations with access to US FDA, WHO-GMP, and EU-GMP approved facilities.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Custom manufacturing services with quote-based pricing |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Anupam Rasayan product offering
Product offeringCore offering
Anupam Rasayan is a custom manufacturer of specialty chemicals operating 8 manufacturing facilities across India and the United States with combined capacity of about 66,000 metric tonnes. The company produces 60+ complex molecules across 30+ commercial chemistries, serving agrochemicals, pharmaceuticals, performance materials, and life sciences sectors. It also operates a CDMO business for custom synthesis of complex molecules and has expanded into finished dosage pharmaceutical formulations through the Bliss GVS Pharma acquisition.
Product overview
Anupam Rasayan India Ltd is a specialty chemicals manufacturer operating as a custom manufacturer of specialty chemicals with a platform-plus-products architecture. The core offering is custom manufacturing of specialty chemicals through proprietary continuous flow chemistry, serving agrochemicals (approximately 45% revenue post-acquisition), pharmaceuticals (~9-10% and growing), and performance materials sectors. Key products include ETFA (Ethyl Trifluoroacetate) manufactured via their continuous flow chemistry platform, with global addressable market of $500-600 million. The company has expanded through acquisitions including US-based Jayhawk Fine Chemicals (advanced custom synthesis for electronics, aerospace, energy, polymers) and India-based Bliss GVS Pharma (finished dosage formulations including suppositories, injectables, tablets with WHO-GMP/EU-GMP approvals). The company operates 6 manufacturing sites with 30,000+ MPTA installed capacity, producing 60+ complex molecules across 30+ commercial chemistries, serving 80+ customers globally.
Differentiator
Problem solved
Functional benefit
Products and services
- Custom Manufacturing of Specialty Chemicals Custom manufacturing of specialty chemicals delivered to agrochemical, pharmaceutical, performance materials, and life sciences customers, supported by R&D capabilities, supply chain management, and backward-integrated facilities.
- ETFA (Ethyl Trifluoroacetate) Fluorinated building block compound manufactured using proprietary continuous flow chemistry, serving as a critical input for pharmaceuticals, life sciences, and performance materials sectors.
- Pharmaceutical Formulations (via Bliss GVS Pharma) Finished dosage formulations including suppositories, injectables, and tablets manufactured at WHO-GMP, US FDA, and EU-GMP approved facilities, serving regulated markets in Africa, Asia, Latin America, Europe, and the US.
- Advanced Custom Synthesis (via Jayhawk Fine Chemicals) Custom synthesis capabilities for electronics, aerospace, energy, and polymers sectors in the US market, with a manufacturing facility in Kansas providing access to regulated North American markets and innovator customers.
- Custom Synthesis and CDMO Services Contract development and manufacturing (CDMO) services providing custom synthesis of complex molecules for pharmaceutical and specialty chemical applications, delivered to global enterprise customers under long-term contracts.
Quantifiable outcome
- 65% YoY revenue growth in FY26 to Rs 23,836 million
- +3 more outcomes
Companies that use Anupam Rasayan
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
Anupam Rasayan technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Anupam Rasayan partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Bliss GVS Pharma LtdcoreAcquisition of 43.3-48.2% stake in Bliss GVS Pharma Ltd for approximately ₹1,369 crore, with mandatory open offer for additional 26% stake at ₹299 per share. The acquisition marks entry into pharmaceutical formulations business with access to US FDA, WHO-GMP, and EU-GMP approved manufacturing facilities. Combined entity creates integrated pharmaceutical manufacturing platform from key starting materials to finished dosage formulations with access to regulated markets including Europe and the United States.
- Jayhawk Fine Chemicals CorporationcoreAcquisition of US-based Jayhawk Fine Chemicals Corporation for approximately $150 million, marking Anupam Rasayan's first manufacturing presence in the United States. The acquisition enhances global footprint and capabilities in high-value chemical segments for electronics and specialty materials. Jayhawk generates significant revenue from electronics, aerospace, energy, and polymers sectors in the US.
Scale indicators14 records
Recent moves7 records
Expansion highlights6 records
Anupam Rasayan competitors and assessment
Company assessmentDirect peers
- Aarti Industries: Indian specialty chemicals manufacturer with a similar custom synthesis and complex molecule portfolio serving agrochemical, pharmaceutical, and performance chemical customers globally. Direct competitor for CDMO contracts in fluorination and intermediates.
- Navin Fluorine International: Indian fluorinated specialty chemicals producer, the most direct competitor on Anupam's ETFA and other fluorinated building block product lines. Overlaps with Anupam's flow chemistry ambitions and pharma/agrochem customer base.
- Divi's Laboratories: Indian API and custom synthesis manufacturer serving global pharma customers with complex molecules and CDMO services. Comparable business model targeting regulated pharma end markets like Anupam's pharmaceutical segment.
- PI Industries: Indian agrochemical CDMO with a custom synthesis model serving global innovators, directly comparable to Anupam's largest agrochemical custom manufacturing segment. Similar enterprise sales motion and contract structure.
- SRF Limited: Indian specialty chemicals company with fluorochemicals, specialty gases, and intermediates exposure. Direct competitor across performance materials and selected pharma intermediates, including fluorinated chemistries.
- Jubilant Ingrevia: Indian specialty chemicals and CDMO player serving pharma, agro, and nutrition end markets. Comparable custom synthesis capability and customer overlap with Anupam's agrochem/pharma verticals.
- Atul Limited: Indian integrated specialty chemicals manufacturer with multi-vertical exposure across agro, pharma, and performance chemicals. Comparable diversification strategy and complex molecule manufacturing.
Broad incumbents
- Solvay: Global specialty chemicals major with a broad portfolio including fluorinated materials and performance chemicals. Larger established player overlapping with Anupam's performance materials and fluorination platform.
- LANXESS: Global specialty chemicals company serving agro, pharma, and industrial customers with intermediates and additives. Broader portfolio player overlapping with several of Anupam's chemistry platforms.
Emerging players
- Shandong Finzone Chemical (Jiangsu Yangnong) / generic Chinese fluorochemical producers: Chinese fluorinated specialty chemical producers with cost-advantaged capacity targeting similar pharma and agro end markets. Represents the principal competitive threat to Anupam's pricing on fluorinated intermediates.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Anupam Rasayan social profiles
Digital presenceAnupam Rasayan compliance and trust
Trust signalCompliance6 records
Anupam Rasayan financial estimates
Financial estimateRevenue estimate
Valuation estimate
Anupam Rasayan leadership team
Management profileNumber of profiles
Profiles10 records
Anupam Rasayan subsidiaries and ownership
Company hierarchySubsidiaries6 records
Anupam Rasayan funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Anupam Rasayan M&A and investment
M&A and investmentM&A1 record
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Anupam Rasayan
What does Anupam Rasayan do?
Anupam Rasayan is a custom manufacturer of specialty chemicals operating 8 manufacturing facilities across India and the United States with combined capacity of about 66,000 metric tonnes. The company produces 60+ complex molecules across 30+ commercial chemistries, serving agrochemicals, pharmaceuticals, performance materials, and life sciences sectors. It also operates a CDMO business for custom synthesis of complex molecules and has expanded into finished dosage pharmaceutical formulations through the Bliss GVS Pharma acquisition.
Is Anupam Rasayan a public or private company?
Anupam Rasayan is a public company. It is classified as public and is currently operating.
When was Anupam Rasayan founded?
Anupam Rasayan was founded in 1984. It employs 1,001 to 5,000 people.
Where is Anupam Rasayan based?
Anupam Rasayan is headquartered in Surat, India, in the Asia region.
How does Anupam Rasayan make money?
Three revenue lines are on record. Specialty Chemicals Manufacturing is the primary driver. The others are custom Synthesis Services and pharmaceutical Formulations.
Who are Anupam Rasayan's main competitors?
Direct peers on record are Aarti Industries, Navin Fluorine International, Divi's Laboratories, PI Industries, SRF Limited, Jubilant Ingrevia and Atul Limited. Broad incumbents are Solvay and LANXESS. Shandong Finzone Chemical (Jiangsu Yangnong) / generic Chinese fluorochemical producers is listed as an emerging player.
Does Anupam Rasayan have an API?
No public API is recorded for Anupam Rasayan.
What industry is Anupam Rasayan in?
Anupam Rasayan's product category is Specialty Chemicals Manufacturing. Its primary akta.pro industry code is AFABAIAI, Custom Synthesis & Technical Active Ingredient (AI) Manufacturing (intermediates, actives), with a secondary code of HLAGABAG, Drug Substance–Drug Product Integrated CDMO. Its NAICS code is 32541 and its SIC code is 2860.